sb 203580 has been researched along with Hibernation, Myocardial in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bassi, R; Bellahcene, M; Cao, X; Dighe, K; Gorog, DA; Kabir, AM; Marber, MS; Quinlan, RA; Tanno, M | 1 |
| Jahania, SA; Keith, BJ; Kristo, G; Lasley, RD; Mentzer, RM; Yoshimura, Y | 1 |
2 other study(ies) available for sb 203580 and Hibernation, Myocardial
| Article | Year |
|---|---|
Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia.
Topics: Animals; Blotting, Western; Enzyme Activation; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardial Stunning; Myocardium; p38 Mitogen-Activated Protein Kinases; Perfusion; Pyridines; Ventricular Dysfunction, Left | 2004 |
The p38 MAPK inhibitor SB203580 blocks adenosine A(1) receptor-induced attenuation of in vivo myocardial stunning.
Topics: Adenosine A1 Receptor Antagonists; Animals; Blood Pressure; Coronary Vessels; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Rate; Imidazoles; Male; Myocardial Stunning; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Receptor, Adenosine A1; Swine; Time Factors; Ventricular Function, Left | 2004 |